Clinical Trial Update: A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study evaluating NN0519-0130 for obesity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• NN0519-0130 (NN0519-0130)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Obesity | Phase 2 | Status: COMPLETED